Zacks Investment Research downgraded Seres Therapeutics Inc (NASDAQ:MCRB) to Sell in a report released today.
- Updated: October 15, 2016
Yesterday Seres Therapeutics Inc (NASDAQ:MCRB) traded 0.09% higher at $11.43. The company’s 50-day moving average is $11.84 and its 200-day moving average is $22.65. The last closing price is down -49.44% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 287,412 shares of the stock were exchanged, down from an average trading volume of 1,325,760
Zacks Investment Research has downgraded Seres Therapeutics Inc (NASDAQ:MCRB) to Sell in a report released on 10/12/2016.
See Chart Below
Seres Therapeutics Inc has a 52 week low of $8.05 and a one year high of $44.51 Seres Therapeutics Inc’s market capitalization is presently $0.
A total of 7 brokerages have released a report on Seres Therapeutics Inc. Five brokerages rating the company a strong buy, one brokerage rating the company a buy, one brokerage rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $43.71.
General Company Details For Seres Therapeutics Inc (NASDAQ:MCRB)
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI, SER-287 to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens. The Company is also conducting research on metabolic diseases, such as early-stage, non-insulin dependent diabetes; obesity and metabolic syndrome; other inflammatory diseases; cancer chemotherapy and immune suppression, and rare genetic diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.